Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer

Tara Sanft, MD
Published: Tuesday, Oct 18, 2016



Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Pertuzumab (Perjeta) plus trastuzumab (Herceptin) with chemotherapy is a better treatment option than trastuzumab and chemotherapy alone, explains Sanft. In patients who receive this therapy prior to surgery, oncologists have seen complete pathologic responses.

In the event of disease progression after such treatment, the next step typically includes T-DM1, which Sanft refers to as a kind of "super Herceptin," as it has been shown to be very effective in metastatic HER2-positive disease and very well-tolerated as a second-line agent.


Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Pertuzumab (Perjeta) plus trastuzumab (Herceptin) with chemotherapy is a better treatment option than trastuzumab and chemotherapy alone, explains Sanft. In patients who receive this therapy prior to surgery, oncologists have seen complete pathologic responses.

In the event of disease progression after such treatment, the next step typically includes T-DM1, which Sanft refers to as a kind of "super Herceptin," as it has been shown to be very effective in metastatic HER2-positive disease and very well-tolerated as a second-line agent.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Publication Bottom Border
Border Publication
x